as 07-26-2024 4:00pm EST
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.
Founded: | 2019 | Country: | United States |
Employees: | N/A | City: | RADNOR |
Market Cap: | 605.7M | IPO Year: | 2023 |
Target Price: | $30.00 | AVG Volume (30 days): | 329.1K |
Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -2.21 | EPS Growth: | N/A |
52 Week Low/High: | $5.85 - $16.91 | Next Earning Date: | 08-05-2024 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Congleton Jon | MLYS | Chief Executive Officer | Jul 11 '24 | Sell | $13.34 | 15,746 | $210,075.26 | 911,212 | SEC Form 4 |
Congleton Jon | MLYS | Chief Executive Officer | Jun 12 '24 | Sell | $12.77 | 16,607 | $212,013.27 | 1,032,461 | SEC Form 4 |
Congleton Jon | MLYS | Chief Executive Officer | Jun 12 '24 | Sell | $12.74 | 39,961 | $509,027.21 | 992,500 | SEC Form 4 |
Congleton Jon | MLYS | Chief Executive Officer | Jun 12 '24 | Sell | $12.52 | 16,229 | $203,162.74 | 976,271 | SEC Form 4 |
Levy Adam Scott | MLYS | CFO and Secretary | Jun 11 '24 | Sell | $12.94 | 96,815 | $1,252,718.33 | 255,462 | SEC Form 4 |
Rodman David Malcom | MLYS | Chief Medical Officer | May 9 '24 | Sell | $15.00 | 100 | $1,500.00 | 66,997 | SEC Form 4 |
Samsara BioCapital GP, LLC | MLYS | 10% Owner | Feb 12 '24 | Buy | $13.50 | 555,555 | $7,499,992.50 | 5,074,916 | SEC Form 4 |
Congleton Jon | MLYS | Chief Executive Officer | Nov 22 '23 | Buy | $5.97 | 4,250 | $25,355.93 | 1,049,068 | SEC Form 4 |
MLYS Breaking Stock News: Dive into MLYS Ticker-Specific Updates for Smart Investing
GuruFocus.com
14 days ago
GuruFocus.com
14 days ago
MT Newswires
17 days ago
GuruFocus.com
a month ago
MT Newswires
a month ago
GuruFocus.com
a month ago
GlobeNewswire
a month ago
GuruFocus.com
a month ago
The information presented on this page, "MLYS Mineralys Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.